Treatment of Ulcerative Colitis
Treatment for ulcerative colitis must be stratified by disease severity: mild-to-moderate disease starts with mesalamine-based therapy, while moderate-to-severe disease requires advanced therapies including biologics or small molecules, with the 2024 AGA guidelines strongly recommending infliximab, vedolizumab, tofacitinib, upadacitinib, ustekinumab, ozanimod, etrasimod, risankizumab, or guselkumab over no treatment. 1
Mild-to-Moderate Ulcerative Colitis
First-Line Therapy
For extensive mild-moderate disease, initiate standard-dose mesalamine (2-3 grams/day) or diazo-bonded 5-ASA as first-line therapy 2. This represents a strong recommendation with moderate quality evidence. Once-daily dosing is preferred over multiple daily doses for improved adherence 2.
Disease location determines route of administration:
- Extensive or left-sided disease: Add rectal mesalamine to oral 5-ASA for superior induction rates 2
- Proctosigmoiditis: Use mesalamine enemas over oral therapy 2
- Proctitis: Use mesalamine suppositories (strong recommendation) 2
Escalation for Inadequate Response
If standard-dose therapy fails or the patient presents with moderate symptoms:
- Escalate to high-dose mesalamine (>3 grams/day) plus rectal mesalamine 2
- If rectal mesalamine is not tolerated, substitute with rectal corticosteroid enemas or foams 2
- If optimized 5-ASA therapy (oral + rectal) fails, add oral prednisone or budesonide MMX 2
Critical pitfall: Avoid probiotics, curcumin, or fecal microbiota transplantation outside clinical trials—these lack evidence and risk delaying effective therapy 2.
Moderate-to-Severe Ulcerative Colitis
Advanced Therapy Selection
The 2024 AGA guidelines provide strong recommendations (moderate-to-high certainty evidence) for multiple advanced therapies 1:
Biologics:
- TNF antagonists: infliximab, golimumab
- Anti-integrin: vedolizumab
- Anti-IL-12/23: ustekinumab
- Anti-IL-23: risankizumab, guselkumab
Small molecules:
- JAK inhibitors: tofacitinib, upadacitinib
- S1P modulators: ozanimod, etrasimod
Conditional recommendations (moderate certainty): adalimumab, filgotinib, mirikizumab 1.
Positioning Strategy Based on Disease Characteristics
For bio-naïve patients with moderate-to-severe disease:
- Consider infliximab, vedolizumab, or ustekinumab as first-line options
- Mirikizumab may be favored in moderate-to-severe disease based on expert opinion 3
- Ozanimod or etrasimod can be considered for mild-to-moderate disease 3
For bio-experienced patients (failed anti-TNF):
- Upadacitinib or mirikizumab are preferred options 3
- Upadacitinib shows maintained efficacy in bio-experienced patients but carries highest adverse event risk 3
- Ozanimod, etrasimod, and mirikizumab show lower clinical remission rates in this population 3
JAK Inhibitor Restrictions
Critical regulatory consideration: In the United States, FDA labeling restricts JAK inhibitors (tofacitinib, filgotinib, upadacitinib) to patients with prior failure or intolerance to TNF antagonists 1. European guidance adds caution for patients ≥65 years, smokers, or those with cardiovascular disease or cancer history 1.
Combination Therapy and Immunomodulators
When to Combine
For TNF antagonists: Combine with immunomodulators (thiopurines) rather than monotherapy (conditional recommendation, low-to-moderate certainty) 1.
For non-TNF biologics: No recommendation exists for combination therapy—use as monotherapy 1.
Immunomodulator Monotherapy
Avoid thiopurine monotherapy for induction (conditional recommendation against) 1. May consider for maintenance of corticosteroid-induced remission only 1.
Avoid methotrexate monotherapy for both induction and maintenance 1.
De-escalation Considerations
Once in corticosteroid-free clinical remission for ≥6 months on TNF antagonist + immunomodulator combination:
- Do not withdraw the TNF antagonist (conditional recommendation against) 1
- No clear guidance on withdrawing immunomodulator—this remains a knowledge gap 1
- Discontinue 5-ASA in patients escalated to advanced therapies who failed 5-ASA 1
Special Considerations
Biosimilars and Formulations
Biosimilars of infliximab, adalimumab, and ustekinumab are equivalent to originators 1. Subcutaneous formulations of infliximab and vedolizumab show comparable efficacy to intravenous maintenance 1.
Extended Induction
For severe disease, consider extended induction regimens (up to 16 weeks) or dose escalation for certain agents 1.
Predictors of Poor Persistence
Shorter disease duration (<7.8 years) and concomitant tacrolimus use predict loss of response to vedolizumab 4. Patients with disease duration <1 year show 32% discontinuation rates due to loss of response 4.
Treatment Goals
Target complete remission: durable symptomatic AND endoscopic remission without corticosteroids 5. This represents the therapeutic ceiling that maximizes quality of life and reduces long-term complications including colectomy (7% at 5 years) and colorectal cancer (4.5% at 20 years) 6.